Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE

Journal of Neuroimmunology

Volumn 79, Issue 2, 1997, Pages 113-118

  Vanderlugt, Carol L ^a   Karandikar, Nitin J ^a   Lenschow, Deborah J ^b   Dal Canto, Mauro C ^a   Bluestone, Jeffrey A ^b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

B7 1; Epitope spreading; Experimental autoimmune encephalomyelitis; Proteolipid protein; SJL J mice; T cell costimulation

Indexed keywords

MONOCLONAL ANTIBODY; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL SPREADING; CELL STIMULATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEMYELINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RECURRENT DISEASE; REMISSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED STRAINS; RECURRENCE; REMISSION INDUCTION;

EID: 0030775998     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00108-2     Document Type: Article

References (24)

1. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 265:1994;1225-1227.
2. Gonatas N.K., Greene M.I., Waksman B.H. Genetic and molecular aspects of demyelination. Immunol. Today. 7:1986;121-126.
3. Greer J.M., Kuchroo V.K., Sobel R.A., Lees M.J. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J. Immunol. 149:1992;783-788.
4. Hirokawa M., Kitabayashi A., Kuroki J., Miura A.B. Signal transduction by B7/BB1 expressed on activated T lymphocytes: Cross-linking of B7/BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunol. 86:1995;155-161.
5. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:1987;302-319.
6. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: A negative regulator of autoimmune disease. J. Exp. Med. 184:1996;783-788.
7. Kennedy M.K., Clatch R.J., Dal Canto M.C., Trotter J.L., Miller S.D. Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses. J. Neuroimmunol. 16:1987;345-364.
8. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell. 80:1995;707-718.
9. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., Linsley P.S., Bluestone J.A. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 257:1992;789-792.
10. Lenschow D.J., Su G.H., Zuckerman L.A., Nabavi N., Jellis C.L., Gray G.S., Miller J., Bluestone J.A. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA. 90:1993;11054-11058.
11. Lenschow D.J., Ho S.C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K.C., Bluestone J.A. Differential effects of anti-B7-1 and anti-B7-2 mAb treatment on the development of diabetes in the NOD mouse. J. Exp. Med. 181:1995;1145-1155.
12. Lenschow D.J., Zeng Y., Hathcock K.S., Zuckerman L.A., Freeman G., Thistlethwaite J.R., Gray G.S., Hodes R.J., Bluestone J.A. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibody. Transplantation. 60:1995;1171-1178.
13. Linsley P.S., Wallace P.M., Johnson J., Gibson M.G., Greene J.L., Ledbetter J.A., Singh C., Tepper M.A. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 257:1992;792-795.
14. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., Miller S.D. Induction of active and adoptive chronic-relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J. Neuroimmunol. 38:1992;229-240.
15. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of EAE in the SJL/J mouse. J. Exp. Med. 182:1995;75-85.
16. Miller S.D., Karpus W.J. The immunopathogenesis and regulation of T-cell mediated demyelinating diseases. Immunol. Today. 15:1994;356-361.
17. Miller S.D., McRae B.L., Vanderlugt C.L., Nikcevich K.M., Pope J.G., Pope L., Karpus W.J. Evolution of the T cell repertoire during the course of experimental autoimmune encephalomyelitis. Immunol. Rev. 144:1995;225-244.
18. Miller S.D., Vanderlugt C.L., Lenschow D.J., Pope J.G., Karandikar N.J., Dal Canto M.C., Bluestone J.A. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:1995;739-745.
19. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol. 7:1989;445-480.
20. Nabavi N., Freeman G.J., Gault A., Godfrey D., Nadler L.M., Glimcher L.H. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature. 360:1992;266-268.
21. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1996;1333-1336.
22. Racke M.K., Scott D.E., Quigley L., Gray G.S., Abe R., June C.H., Perrin P.J. Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96:1995;195-203.
23. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., Thompson C.B., Bluestone J.A. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:1994;405-413.
24. Wekerle H. Immunopathogenesis of multiple sclerosis. Acta Neurol. 13:1991;197-204.